BDL Solutions
Divestiture and licensing opportunities for a pre-clinical product
March 6, 20262.4K views
1
Objective
- Prioritizing indications to understand commercial opportunity of an existing pipeline product to create strategies or licensing opportunities
- Create strategies and scenarios for divestiture or licensing opportunities
2
Approach
- Evaluate Mechanism of Action and clinical trial feasibility of the pre-clinical product
- Assess 25 indications for clinical evidence, trial feasibility, unmet need, KOL perspective and market potential
- Analyze market opportunities for the top indications using KOL insights
- Forecast revenue and value for the top 4 indications
3
Outcome
- Identified 25 indications based on strategy and clinical evidence
- Ranked 25 indications through KOL interviews, selecting the top 10
- Conducted qualitative interviews with KOLs to assess product placement and Target Product Profile (TPP) reaction, identifying the top 4 market opportunities
- Forecasted revenue and valuation for the top 4 indications
4
Client Benefits
- Helped the client understand the commercial potential of the product across 25 indications
- Our analysis enabled them to decide whether to prioritize clinical development or divest the product
- Trial prioritization helped the client identify high-potential indications with unmet needs